Antitumoral effect of Ocoxin in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is becoming one of the most prevalent types of cancer worldwide. The most efficient types of treatment at present include surgical resection and liver transplantation, but these treatments may only be used in a small percentage of patients. In order to identify novel t...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 14; no. 2; pp. 1950 - 1958
Main Authors Díaz-Rodríguez, Elena, El-Mallah, Al-Mahy, Sanz, Eduardo, Pandiella, Atanasio
Format Journal Article
LanguageEnglish
Published Greece D.A. Spandidos 01.08.2017
Spandidos Publications
Spandidos Publications UK Ltd
Subjects
Antibiotics
antioxidants
Apoptosis
Cancer therapies
Cell cycle
Development and progression
Dietary supplements
Disease
Drug therapy
Drugs
Health aspects
Hepatocellular carcinoma
Immunoglobulins
Kinases
Laboratories
Liver cancer
Oncology
Studies
antioxidants
cell cycle
hepatocellular carcinoma
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is becoming one of the most prevalent types of cancer worldwide. The most efficient types of treatment at present include surgical resection and liver transplantation, but these treatments may only be used in a small percentage of patients. In order to identify novel therapeutic strategies for this disease, the present study explored the potential antitumoral effect of Ocoxin® oral solution (OOS) in HCC. OOS inhibited the proliferation of HCC cell lines in a time- and dose-dependent manner, being more efficient when used in combination with sorafenib, a standard of care treatment for patients diagnosed with advanced-stage disease. Mechanistic studies indicated that the effect of OOS was due to the induction of cell cycle arrest rather than the stimulation of apoptotic cell death. The cell cycle was slowed down in all phases in the HCC cell lines treated with OOS. Finally, when tested in animal models of HCC, OOS reduced tumor progression through the induction of necrosis in xenograft tumor models. Considering the poor prognosis and high resistance to antitumor treatments of HCC, the antiproliferative action of OOS, particularly in combination with sorafenib, provides the opportunity to investigate the effect of combined therapy in a clinical setting.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current address: 3Zoology Department, Faculty of Science, Beni-Suef University, Beni Suef 62511, Egypt
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2017.6440